Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.38 |
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.36 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.36 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834490 | 0.97 | TSHR (0.41) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| Ammonia Solution, Strong SCHEMBL8197954 | 0.95 | TSHR (0.40) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| Bromide SCHEMBL11552674 | 0.95 | TSHR (0.40) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| SCHEMBL538480 | 0.89 | CYP1A2 (0.45) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| SCHEMBL30148931 | 0.89 | CYP1A2 (0.45) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| SCHEMBL31180772 | 0.87 | ACHE (0.39) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| SCHEMBL3679087 | 0.87 | ACHE (0.39) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| Hydrochloric Acid SCHEMBL4638285 | 0.87 | RAB9A (0.41) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| SCHEMBL3073449 | 0.84 | CYP1A2 (0.41) | KDM4EALDH1A1TSHRRAB9ACYP3A4 | |
| SCHEMBL18923214 | 0.84 | CYP1A2 (0.41) | KDM4EALDH1A1TSHRRAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8206673-B2 | Method of preparing boron-nitrogen compounds | WILDCAT DISCOVERY TECHNOLOGIES (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110064640-A1 | METHOD OF PREPARING BORON-NITROGEN COMPOUNDS | WILDCAT DISCOVERY TECHNOLOGIES (US) | 2011-03-17 | — | — | US | disclosed |
| US-6806371-B2 | BY MEANS OF PHASE TRANSFER CATALYSIS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2004-10-19 | — | — | US | disclosed |
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2004-04-01 | — | — | US | disclosed |
| EP-0269884-B1 | CATALYZED ALKYLATION OF HALOPYRIDINATES IN THE ABSENCE OF ADDED ORGANIC SOLVENTS | DOWELANCO (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0277292-B1 | ORGANIC SOLVENT-FREE PROCESS FOR PREPARING PYRIMIDINYL ORGANOPHOSPHATES | THE DOW CHEMICAL COMPANY (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0269884-A1 | Catalyzed alkylation of halopyridinates in the absence of added organic solvents | DOWELANCO (US) | 1988-06-08 | — | — | EP | disclosed |
| US-4701531-A | Catalyzed alkylation of halopyridinates in the absence of added organic solvents | THE DOW CHEMICAL COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4699634-A | SEMIPERMEABLE MEMBRANES | THE STANDARD OIL COMPANY (US) | 1987-10-13 | — | — | US | disclosed |
| US-4546189-A | Preparation of cyano(6-(substituted phenoxy)-2-pyridinyl)methyl esters of 3-(2,2-dihaloethenyl)-2,2-dimethylcyclopropane carboxylic acids | THE DOW CHEMICAL COMPANY (US) | 1985-10-08 | — | — | US | disclosed |
| US-4086253-A | 3,3',5,5'-Tetra-substituted diphenoquinone from 2,6-disubstituted phenol by phase-transfer catalysis | THE DOW CHEMICAL COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-4028439-A | QUATERNARY AMMONIUM SALT AND IMIDAZOLE CATALYSTS | THE DOW CHEMICAL COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
| US-4016225-A | WITH QUATERNARY AMMONIUM SALT AND 1,4-DIAZABICYCLO(2.2.2)OCTANE CATALYST | THE DOW CHEMICAL COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
| US-4014891-A | FROM AN ALKALI METAL ARYL MERCAPTIDE AND BROMOCHLOROMETHANE IN A QUATERNARY AMMONIUM SALT | THE DOW CHEMICAL COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-4007197-A | QUATERNARY AMMONIUM OR PHOSPHONIUM SALT AND TERTIARY AMINE CATALYST | THE DOW CHEMICAL COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-4001293-A | Process for production of γ-halonitriles | THE DOW CHEMICAL COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3996259-A | QUATERNARY AMMONIUM OR PHOSPHONIUM SALT | THE DOW CHEMICAL COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3974199-A | Process for production of cyclopropylcyanide | THE DOW CHEMICAL COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
| US-3972887-A | QUATERNARY AMMONIUM SALT CATALYST | THE DOW CHEMICAL COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
| US-3969360-A | Catalyzed alkylation of halopyridinates | THE DOW CHEMICAL COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | HRH2, SCO2, CBR1 | ACHE 4055/4885GLA 4354/4885GAA 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.